share_log
Benzinga ·  Jul 22 08:17
Cassava Sciences' Phase 3 Trial Expected To Conclude By December 2024 With 804 Patients; Second Trial With 1,125 Patients To End By June 2025; Successful Results Could Be Revolutionary
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment